Abstract |
Forty-two patients with advanced head and neck cancer entered this phase II trial of long-term continuous 5-fluorouracil (5-FU) infusion at a dose of 300 mg/m2/day for a maximum of 16 weeks. Objective response rate was 15% in 41 evaluable patients. Median time to progression was 2.9 months, and median survival 4 months. Toxicity was generally mild. Reversible stomatic and hand-foot syndrome WHO grade III-IV was observed in 5 and 3 patients, respectively. Haematologic toxicity and emesis were less pronounced with no grade III-IV toxicity. One patient had to discontinue treatment because of ataxia. No catheter-related toxicity and no treatment-related mortality were observed. In the present study long-term continuous infusion of 5-FU has only modest activity in terms of response rate, but the activity is comparable with other single-agent regimens. The treatment is well tolerated, with minimal toxicity making it usable in a palliative situation.
|
Authors | P Sørensen, L J Andersen, O Hansen, L Bastholt |
Journal | Acta oncologica (Stockholm, Sweden)
(Acta Oncol)
Vol. 38
Issue 8
Pg. 1043-5
( 1999)
ISSN: 0284-186X [Print] England |
PMID | 10665760
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Fluorouracil
|
Topics |
- Adolescent
- Adult
- Aged
- Antimetabolites, Antineoplastic
(administration & dosage, adverse effects)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Head and Neck Neoplasms
(drug therapy)
- Humans
- Infusion Pumps
- Infusions, Intravenous
- Male
- Middle Aged
- Palliative Care
- Survival Rate
|